10-Q: Accolade Inc. Reports Q3 2025 Results, Announces Merger Agreement with Transcarent

Accolade Inc. released its third quarter fiscal year 2025 results, reporting a net loss and a goodwill impairment charge, while also announcing a definitive merger agreement with Transcarent.

Summary

• Accolade, Inc. reported a net loss of $121.3 million for the three months ended November 30, 2024, compared to a net loss of $21.1 million for the same period last year.
• The company's revenue for the quarter was $105.1 million, a 6% increase year-over-year.
• A significant goodwill impairment charge of $96.5 million was recorded during the quarter.
• For the nine months ended November 30, 2024, the net loss was $172.8 million, compared to a net loss of $92.3 million for the same period in 2023.
• The company's revenue for the nine months was $321.9 million, an 11% increase year-over-year.
• Accolade has entered into a merger agreement with Transcarent, Inc., where Accolade will be acquired for $7.03 per share in cash.
• As of December 31, 2024, 81,585,508 shares of the company's common stock were outstanding.

Sentiment

Score: 3

Explanation: The document presents a mixed picture with revenue growth offset by significant losses and a goodwill impairment. The merger announcement adds uncertainty, resulting in a negative sentiment overall.

Positives

• Revenue increased by 6% in Q3 2025 and 11% for the first nine months of fiscal year 2025, indicating continued growth in the business.
• Usage-based fees increased by 18% in Q3 2025 and 24% for the first nine months of fiscal year 2025, showing strong demand for the company's services.
• The company has a revolving credit facility with a capacity of $61.7 million as of November 30, 2024, providing access to additional capital if needed.

Negatives

• The company reported a significant net loss of $121.3 million in Q3 2025, a substantial increase from the $21.1 million loss in Q3 2024.
• A goodwill impairment charge of $96.5 million was recorded, indicating a decrease in the value of the company's assets.
• Operating expenses increased significantly, driven by the goodwill impairment charge.
• The company's net loss for the first nine months of fiscal year 2025 was $172.8 million, a significant increase from the $92.3 million loss in the same period last year.

Risks

• The company's financial performance is subject to risks related to the achievement of performance-based revenue, which is variable and dependent on factors outside of the company's control.
• The company's business is subject to macroeconomic factors, including inflation and geopolitical risk, which could impact customer spending and demand for services.
• The pending merger with Transcarent could have an adverse effect on the company's business, operating results, and stock price, and may result in the loss of employees, customers, and other business partners.
• The merger agreement includes restrictions on the conduct of the company's business prior to the completion of the merger, which could limit its ability to respond to competitive pressures and future business opportunities.
• The failure to complete the merger may adversely affect the company's business and stock price.

Future Outlook

The company's future performance is subject to various factors, including the achievement of performance-based revenue, macroeconomic conditions, and the outcome of the proposed merger with Transcarent. The company expects cost of revenue, excluding depreciation and amortization, to increase along with revenue growth over time but decrease as a percentage of revenue. Over time, the company expects product and technology expenses and general and administrative expenses to decrease as a percentage of revenue. The company expects sales and marketing expense to increase in absolute dollars but remain relatively stable as a percentage of revenue over time.

Management Comments

• Management believes the company's cash, cash equivalents, and marketable securities, plus customer revenues and advances and available borrowings under its debt facility, are sufficient to fund its operations through at least the next 12 months.
• Management believes the 70% weighting to the income-based approach is appropriate as it more directly reflects its future growth and profitability expectations.

Industry Context

The document highlights the company's position in the healthcare navigation and virtual care market, emphasizing its technology-enabled solutions and integrated capabilities. The proposed merger with Transcarent suggests a move towards consolidation in the industry, potentially driven by the need to offer more comprehensive and integrated healthcare solutions. The company's focus on cost savings and improved health outcomes aligns with broader industry trends.

Comparison to Industry Standards

• The company's revenue growth of 6% in Q3 2025 and 11% for the first nine months of fiscal year 2025 is moderate compared to some high-growth technology companies in the healthcare sector, but is in line with other established players in the healthcare navigation space.
• The significant net loss and goodwill impairment charge indicate potential challenges in profitability and asset valuation, which may be worse than some of its peers.
• The merger with Transcarent is a strategic move that could position the combined entity to better compete with larger, more established healthcare providers and technology companies.
• The company's focus on a recurring per-member-per-month (PMPM) fee model is a common practice in the healthcare benefits industry, but the variable component based on performance metrics and cost savings adds complexity and risk.
• The company's adjusted gross margin of 45.6% in Q3 2025 and 46.9% for the first nine months of fiscal year 2025 is within the range of other healthcare technology companies, but the company needs to continue to improve its operational efficiencies to improve this metric.

Management Changes

Legal Proceedings

• The company is involved in various claims, inquiries, and legal actions arising in the ordinary course of business, but management does not expect these to have a material adverse effect on the company's financial position or liquidity.

Stakeholder Impact

• Shareholders will be impacted by the proposed merger with Transcarent, receiving $7.03 per share in cash.
• Employees may experience uncertainty regarding their future roles and relationships with the company following the completion of the merger.
• Customers may be affected by changes in the company's operations and service offerings as a result of the merger.
• Suppliers and other business partners may be impacted by the merger and potential changes in the company's business relationships.

Next Steps

• The company will convene a stockholder meeting to vote on the merger agreement with Transcarent.
• The company will continue to operate its business in the ordinary course, subject to the restrictions outlined in the merger agreement.
• The company will work to obtain regulatory approvals for the merger.

Key Dates

Keywords

healthcare, advocacy, virtual primary care, expert medical opinion, merger, acquisition, goodwill impairment, revenue, net loss, financial results